S3. Pharmacy identification

Findings from this criterion

Compounded GLP-1 labels: concentration, volume and units Syringe units, liquid volume and the amount of medication describe different things. A familiar syringe marking cannot establish a dose when the concentration or prescription has changed. Ask the dispensing pharmacist to reconcile the prescription, label and supplied syringe.

How can a named compounding pharmacy be verified? Start with the dispensing pharmacy's exact name and address, then compare them with the relevant state pharmacy board record. A seller's logo or partner list is insufficient.

What does 503A or 503B actually establish about a seller? 503A and 503B describe different federal compounding frameworks. Neither label identifies the filling facility by itself, and neither makes a compounded drug FDA-approved.

How many peptide sellers name the pharmacy that fills the order? A minority. Most sellers substitute a legal category, such as a licensed 503A pharmacy, for a facility a reader could look up in a state board register.

Which pharmacies fill the orders, and how many sellers name the same one? Fewer facilities than storefronts. Several sellers that look like separate businesses name the same filling pharmacy, and one facility appears in the ledger under several different spellings, each written by a different seller.

The question the regulator asked, and whether the record answers it Some answer it and some do not. The letters and the criterion ask the same question, and this piece reports only the dated state of both, because the ledger holds no earlier reading of those pages to compare against.

Where does the material come from, and what does FDA's GLP-1 import alert say? Almost no seller names where its active ingredient is made. Many say compounded or made in the USA, which describes where a vial was finished, and FDA's import alert shows the GLP-1 ingredient supply is largely foreign.